SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.
Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), azienda di dispositivi medici specializzata nei disturbi sacropelvici, parteciper脿 al Morgan Stanley 23rd Annual Global Healthcare Conference a New York. Il management terr脿 un fireside chat il 9 settembre 2025 alle 4:00 PT / 7:00 ET.
Gli investitori potranno seguire la presentazione previa registrazione; sar脿 inoltre disponibile un webcast in diretta sul sito per gli investor relations di SI-BONE. La registrazione del webcast rester脿 accessibile per almeno 90 giorni dopo l'evento.
SI-BONE (Nasdaq: SIBN), compa帽铆a de dispositivos m茅dicos centrada en trastornos sacrop茅lvicos, participar谩 en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York. La direcci贸n ofrecer谩 un fireside chat el 9 de septiembre de 2025 a las 4:00 PT / 7:00 ET.
Los inversores podr谩n acceder a la presentaci贸n registr谩ndose; habr谩 adem谩s una transmisi贸n en vivo (webcast) disponible en la web de relaciones con inversionistas de SI-BONE. La grabaci贸n del webcast permanecer谩 disponible al menos 90 d铆as tras el evento.
SI-BONE (Nasdaq: SIBN)鞚� 觳滉敞路鞛リ敞 攵�鞙� 歆堩櫂(sacropelvic disorders)鞐� 欤茧牓頃橂姅 鞚橂旮瓣赴 須岇偓搿�, 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀戈皜頃╇媹雼�. 須岇偓 瓴届榿歆勳潃 2025雲� 9鞗� 9鞚� 04:00 PT / 07:00 ET鞐� 韺岇澊鞏挫偓鞚措摐 毂楈潉 歆勴枆頃╇媹雼�.
韴瀽鞛愲姅 霌彪鞚� 韱淀暣 氚滍憸 鞛愲鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, SI-BONE鞚� IR 靷澊韸胳棎靹� 霛检澊敫� 鞗箘旌愳姢韸戈皜 鞝滉车霅╇媹雼�. 鞗箘旌愳姢韸� 雲鬼檾氤胳潃 頄夓偓 膦呺 頉� 斓滌唽 90鞚缄皠 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
SI-BONE (Nasdaq: SIBN), une soci茅t茅 de dispositifs m茅dicaux sp茅cialis茅e dans les troubles sacro-pelviens, participera 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference 脿 New York. La direction tiendra un fireside chat le 9 septembre 2025 脿 04:00 PT / 07:00 ET.
Les investisseurs pourront acc茅der 脿 la pr茅sentation en s'inscrivant ; un webcast en direct sera 茅galement disponible sur le site des relations investisseurs de SI-BONE. L'enregistrement du webcast restera accessible pendant au moins 90 jours apr猫s l'茅v茅nement.
SI-BONE (Nasdaq: SIBN), ein Medizintechnikunternehmen mit Fokus auf sakropelvine Erkrankungen, wird an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York teilnehmen. Das Management f眉hrt am 9. September 2025 um 04:00 PT / 07:00 ET ein Fireside-Chat durch.
Investoren k枚nnen die Pr盲sentation nach Registrierung abrufen; zudem wird ein Live-Webcast auf der Investor-Relations-Website von SI-BONE verf眉gbar sein. Die Aufzeichnung des Webcasts bleibt mindestens 90 Tage nach der Veranstaltung zug盲nglich.
- None.
- None.
SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:聽. Live audio of the webcast will be available on the 鈥淚nvestors鈥� section of the company鈥檚 website at: . The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
厂滨-叠翱狈贰听(狈础厂顿础蚕: SIBN)聽is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System庐,聽SI-BONE聽has supported over 4,600 physicians in performing a total of nearly 130,000 procedures. A unique body of clinical evidence supports the use of SI-BONE鈥檚 technologies with over 175 peer reviewed publications including four randomized controlled trials.聽SI-BONE聽has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visit .
SI-BONE, Sacropelvic Solutions, iFuse Implant System庐, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. 漏2025 SI-BONE, Inc. All Rights Reserved.聽
Investor Contact: Saqib Iqbal
FAQ
When is SI-BONE (SIBN) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access SI-BONE's (SIBN) Morgan Stanley conference presentation?
How long will SI-BONE's (SIBN) Morgan Stanley conference presentation be available for replay?
What type of medical devices does SI-BONE (SIBN) specialize in?
